Effects of Ranolazine on Quality of Life Among Patients With Diabetes Mellitus and Stable Angina
What is the effect of ranolazine on patients’ self-reported health status and quality of life?
This was an analysis of patient-level outcomes in patients participating in the TERISA (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina) trial. TERISA was a randomized, double-blind, placebo-controlled trial in which patients with chronic stable angina and type 2 diabetes mellitus (T2DM) were randomized to placebo or ranolazine. Health status/quality of life were assessed with the Seattle Angina Questionnaire (SAQ), Rose Dyspnea Scale, and the Medical Outcomes Short Form-36 (SF-36).
Compared with placebo, ranolazine significantly improved SAQ angina frequency, treatment satisfaction, and SF-36 physical component summary scales. Compared with placebo, a greater percentage of patients treated with ranolazine had at least a 10-point improvement in SAQ angina frequency scores (67% vs. 58%, p = 0.004).
Ranolazine is associated with improved patient-reported measures of disease-specific and generic health status.
The investigators of the TERISA trial previously reported that ranolazine reduced the frequency of angina episodes and use of sublingual nitroglycerin in patients with T2DM and stable angina. The current study adds to that data, now demonstrating the role of ranolazine in improving patient-level health status and quality of life, particularly among those patients with more severe angina.
Keywords: Angina, Stable, Quality of Life, Diabetes Mellitus, Type 2, Personal Satisfaction, Piperazines, Questionnaires, Dyspnea, Health Status, Nitroglycerin
< Back to Listings